1338789-07-3 Usage
Description
1-(2-phenylethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one is a complex chemical compound belonging to the pyrazolopyrimidine class. It features a pyrazolo[3,4-d]pyrimidin-4-one core with a 2-phenylethyl substituent, which may contribute to its potential biological and pharmacological activities.
Uses
Used in Pharmaceutical Industry:
1-(2-phenylethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one is used as a potential therapeutic agent for various medical conditions due to its complex structure and the pharmacological properties associated with the pyrazolopyrimidine class of compounds.
Used in Research and Development:
In the field of drug discovery and development, 1-(2-phenylethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one serves as a valuable compound for studying its interactions with biological targets and exploring its potential as a lead molecule for the development of new drugs.
Used in Chemical Synthesis:
1-(2-phenylethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one can also be utilized as a synthetic intermediate or building block in the creation of more complex molecules with specific applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 1338789-07-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,8,7,8 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1338789-07:
(9*1)+(8*3)+(7*3)+(6*8)+(5*7)+(4*8)+(3*9)+(2*0)+(1*7)=203
203 % 10 = 3
So 1338789-07-3 is a valid CAS Registry Number.
1338789-07-3Relevant articles and documents
Structure-based optimization of tyrosine kinase inhibitor CLM3. design, synthesis, functional evaluation, and molecular modeling studies.
Sartini, Stefania,Coviello, Vito,Bruno, Agostino,La Pietra, Valeria,Marinelli, Luciana,Simorini, Francesca,Taliani, Sabrina,Salerno, Silvia,Marini, Anna Maria,Fioravanti, Anna,Orlandi, Paola,Antonelli, Alessandro,Da Settimo, Federico,Novellino, Ettore,Bocci, Guido,La Motta, Concettina
, p. 1225 - 1235 (2014/03/21)
Recent advances in the knowledge of thyroid carcinomas development identified receptor tyrosine kinases, like VEGFR2 and RET, as viable and promising targets. Accordingly, their inhibition is emerging as the major therapeutic strategy to treat these pathologies. In this study we describe the synthesis and the functional evaluation of three different series of 4-substituted pyrazolo[3,4-d]pyrimidine derivatives, 8a-g, 9a-g, and 10a-g, designed exploiting a structure-based optimization of the previously developed inhibitor CLM3. Compared to the lead, the novel compounds markedly improved both their inhibitory profile against the target proteins, VEGFR2 and RET, and their antiproliferative efficacy against the medullary thyroid cancer cell line TT. Significantly, compounds 8b, 9c, and 10c proved to block the kinase activity of the mutant RETV804L, which still lacks effective inhibitors.
